Sleep Disorders Prior to Adjuvant Radiation Therapy for Gynecological Malignancies.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 12 07 2021
revised: 22 07 2021
accepted: 23 07 2021
entrez: 3 9 2021
pubmed: 4 9 2021
medline: 11 9 2021
Statut: ppublish

Résumé

Many patients with gynecological malignancies receive postoperative radiotherapy, which can lead to fear and sleep disorders. We aimed to identify the prevalence of and risk factors for sleep disorders. Sixty-two patients assigned to radiotherapy for gynecological malignancies were retrospectively evaluated. Seventeen characteristics were analyzed for associations with pre-radiotherapy sleep disorders including age, Karnofsky performance score, Charlson comorbidity index, history of additional malignancy, family history of gynecological cancer, distress score, emotional, physical or practical problems, tumor site/stage; chemotherapy, treatment volume, brachytherapy, and the COVID-19 pandemic. The prevalence of pre-radiotherapy sleep disorders was 46.8%. Sleep disorders were significantly associated with Charlson comorbidity index ≥3 (p=0.012), greater number of physical problems (p<0.0001), and advanced primary tumor stage (p=0.005). A trend was found for greater number of emotional problems (p=0.075). Pre-radiotherapy sleep disorders are common in patients with gynecological malignancies, particularly in those with specific risk factors. Patients should be offered early psychological support.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Many patients with gynecological malignancies receive postoperative radiotherapy, which can lead to fear and sleep disorders. We aimed to identify the prevalence of and risk factors for sleep disorders.
PATIENTS AND METHODS METHODS
Sixty-two patients assigned to radiotherapy for gynecological malignancies were retrospectively evaluated. Seventeen characteristics were analyzed for associations with pre-radiotherapy sleep disorders including age, Karnofsky performance score, Charlson comorbidity index, history of additional malignancy, family history of gynecological cancer, distress score, emotional, physical or practical problems, tumor site/stage; chemotherapy, treatment volume, brachytherapy, and the COVID-19 pandemic.
RESULTS RESULTS
The prevalence of pre-radiotherapy sleep disorders was 46.8%. Sleep disorders were significantly associated with Charlson comorbidity index ≥3 (p=0.012), greater number of physical problems (p<0.0001), and advanced primary tumor stage (p=0.005). A trend was found for greater number of emotional problems (p=0.075).
CONCLUSION CONCLUSIONS
Pre-radiotherapy sleep disorders are common in patients with gynecological malignancies, particularly in those with specific risk factors. Patients should be offered early psychological support.

Identifiants

pubmed: 34475061
pii: 41/9/4407
doi: 10.21873/anticanres.15246
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4407-4410

Informations de copyright

Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Dirk Rades (D)

Department of Radiation Oncology, University of Lübeck, Lübeck, Germany; dirk.rades@uksh.de.

Svenja Kopelke (S)

Department of Radiation Oncology, University of Lübeck, Lübeck, Germany.
Department of Hematology and Oncology, University of Lübeck, Lübeck, Germany.

Tamer Soror (T)

Department of Radiation Oncology, University of Lübeck, Lübeck, Germany.

Steven E Schild (SE)

Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A.

Soeren Tvilsted (S)

Research Projects and Clinical Optimization, Zealand University Hospital, Koege, Denmark.

Troels W Kjaer (TW)

Neurological Department, Zealand University Hospital, Roskilde, Denmark.

Tobias Bartscht (T)

Department of Hematology and Oncology, University of Lübeck, Lübeck, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH